Information Provided By:
Fly News Breaks for June 4, 2015
ABT
Jun 4, 2015 | 06:32 EDT
BTIG initiated Abbot with a Buy rating and $56 price target. The firm said Abbot's Vascular and Nutritional product outlooks are improving and its strategy with established pharmaceuticals within emerging markets to license products into a strong distribution channel will continue to drive double-digit revenue growth.